nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Topoisomerase Inhibitors—Teniposide—lymphatic system cancer	0.409	0.569	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Mitoxantrone—lymphatic system cancer	0.31	0.431	CiPCiCtD
Epirubicin—TOP2A—Teniposide—lymphatic system cancer	0.079	0.398	CbGbCtD
Epirubicin—TOP2A—Mitoxantrone—lymphatic system cancer	0.0553	0.278	CbGbCtD
Epirubicin—ABCC1—Mitoxantrone—lymphatic system cancer	0.0306	0.154	CbGbCtD
Epirubicin—ABCC1—Vincristine—lymphatic system cancer	0.0211	0.106	CbGbCtD
Epirubicin—ABCC1—Methotrexate—lymphatic system cancer	0.0128	0.0642	CbGbCtD
Epirubicin—AURKA—Etoposide—Teniposide—lymphatic system cancer	0.000401	0.196	CbGdCrCtD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—lymphatic system cancer	0.000256	0.125	CbGdCrCtD
Epirubicin—TOP2A—Etoposide—Teniposide—lymphatic system cancer	0.000153	0.0748	CbGdCrCtD
Epirubicin—AURKA—Cladribine—Fludarabine—lymphatic system cancer	0.000138	0.0672	CbGdCrCtD
Epirubicin—AURKA—Clofarabine—Fludarabine—lymphatic system cancer	0.000127	0.0621	CbGdCrCtD
Epirubicin—AURKA—Clofarabine—Cytarabine—lymphatic system cancer	0.00012	0.0587	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Teniposide—lymphatic system cancer	0.000117	0.057	CbGdCrCtD
Epirubicin—AURKA—Gemcitabine—Cytarabine—lymphatic system cancer	0.000111	0.0544	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vincristine—lymphatic system cancer	0.00011	0.0538	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Fludarabine—lymphatic system cancer	0.000108	0.0529	CbGdCrCtD
Epirubicin—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	6.96e-05	0.0339	CbGdCrCtD
Epirubicin—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	5.27e-05	0.0257	CbGdCrCtD
Epirubicin—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	4.87e-05	0.0237	CbGdCrCtD
Epirubicin—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	4.79e-05	0.0233	CbGdCrCtD
Epirubicin—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	4.6e-05	0.0224	CbGdCrCtD
Epirubicin—Dermatitis—Teniposide—lymphatic system cancer	4.53e-05	0.00057	CcSEcCtD
Epirubicin—Dysgeusia—Mitoxantrone—lymphatic system cancer	4.51e-05	0.000568	CcSEcCtD
Epirubicin—Headache—Teniposide—lymphatic system cancer	4.51e-05	0.000567	CcSEcCtD
Epirubicin—Pruritus—Fludarabine—lymphatic system cancer	4.47e-05	0.000563	CcSEcCtD
Epirubicin—Lymphadenopathy—Methotrexate—lymphatic system cancer	4.47e-05	0.000562	CcSEcCtD
Epirubicin—Back pain—Mitoxantrone—lymphatic system cancer	4.46e-05	0.000561	CcSEcCtD
Epirubicin—Leukopenia—Carmustine—lymphatic system cancer	4.44e-05	0.000558	CcSEcCtD
Epirubicin—Anorexia—Bleomycin—lymphatic system cancer	4.42e-05	0.000556	CcSEcCtD
Epirubicin—Thrombophlebitis—Methotrexate—lymphatic system cancer	4.4e-05	0.000554	CcSEcCtD
Epirubicin—Diabetes mellitus—Methotrexate—lymphatic system cancer	4.38e-05	0.000551	CcSEcCtD
Epirubicin—Anaemia—Vincristine—lymphatic system cancer	4.37e-05	0.00055	CcSEcCtD
Epirubicin—Agitation—Vincristine—lymphatic system cancer	4.35e-05	0.000547	CcSEcCtD
Epirubicin—Vision blurred—Mitoxantrone—lymphatic system cancer	4.34e-05	0.000546	CcSEcCtD
Epirubicin—Photosensitivity—Methotrexate—lymphatic system cancer	4.34e-05	0.000546	CcSEcCtD
Epirubicin—Hypotension—Bleomycin—lymphatic system cancer	4.33e-05	0.000545	CcSEcCtD
Epirubicin—Diarrhoea—Fludarabine—lymphatic system cancer	4.32e-05	0.000544	CcSEcCtD
Epirubicin—Convulsion—Carmustine—lymphatic system cancer	4.29e-05	0.00054	CcSEcCtD
Epirubicin—Hypertension—Carmustine—lymphatic system cancer	4.28e-05	0.000538	CcSEcCtD
Epirubicin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	4.28e-05	0.000538	CcSEcCtD
Epirubicin—Nausea—Teniposide—lymphatic system cancer	4.27e-05	0.000537	CcSEcCtD
Epirubicin—Anaemia—Mitoxantrone—lymphatic system cancer	4.26e-05	0.000536	CcSEcCtD
Epirubicin—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	4.26e-05	0.0208	CbGdCrCtD
Epirubicin—Vertigo—Vincristine—lymphatic system cancer	4.25e-05	0.000535	CcSEcCtD
Epirubicin—Hepatic failure—Methotrexate—lymphatic system cancer	4.24e-05	0.000534	CcSEcCtD
Epirubicin—Leukopenia—Vincristine—lymphatic system cancer	4.24e-05	0.000533	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	4.22e-05	0.000531	CcSEcCtD
Epirubicin—Chest pain—Carmustine—lymphatic system cancer	4.22e-05	0.000531	CcSEcCtD
Epirubicin—Myalgia—Carmustine—lymphatic system cancer	4.22e-05	0.000531	CcSEcCtD
Epirubicin—Anxiety—Carmustine—lymphatic system cancer	4.21e-05	0.000529	CcSEcCtD
Epirubicin—Paraesthesia—Bleomycin—lymphatic system cancer	4.16e-05	0.000523	CcSEcCtD
Epirubicin—Malaise—Mitoxantrone—lymphatic system cancer	4.16e-05	0.000523	CcSEcCtD
Epirubicin—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	4.14e-05	0.0202	CbGdCrCtD
Epirubicin—Dyspnoea—Bleomycin—lymphatic system cancer	4.13e-05	0.00052	CcSEcCtD
Epirubicin—Renal failure acute—Methotrexate—lymphatic system cancer	4.13e-05	0.000519	CcSEcCtD
Epirubicin—Leukopenia—Mitoxantrone—lymphatic system cancer	4.12e-05	0.000519	CcSEcCtD
Epirubicin—Convulsion—Vincristine—lymphatic system cancer	4.1e-05	0.000516	CcSEcCtD
Epirubicin—Hypertension—Vincristine—lymphatic system cancer	4.09e-05	0.000514	CcSEcCtD
Epirubicin—Confusional state—Carmustine—lymphatic system cancer	4.08e-05	0.000513	CcSEcCtD
Epirubicin—Oedema—Carmustine—lymphatic system cancer	4.05e-05	0.000509	CcSEcCtD
Epirubicin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	4.04e-05	0.000508	CcSEcCtD
Epirubicin—Decreased appetite—Bleomycin—lymphatic system cancer	4.03e-05	0.000507	CcSEcCtD
Epirubicin—Myalgia—Vincristine—lymphatic system cancer	4.03e-05	0.000507	CcSEcCtD
Epirubicin—Cough—Mitoxantrone—lymphatic system cancer	4.02e-05	0.000506	CcSEcCtD
Epirubicin—Infection—Carmustine—lymphatic system cancer	4.02e-05	0.000506	CcSEcCtD
Epirubicin—Vomiting—Fludarabine—lymphatic system cancer	4.02e-05	0.000506	CcSEcCtD
Epirubicin—Convulsion—Mitoxantrone—lymphatic system cancer	3.99e-05	0.000502	CcSEcCtD
Epirubicin—Rash—Fludarabine—lymphatic system cancer	3.99e-05	0.000501	CcSEcCtD
Epirubicin—Dermatitis—Fludarabine—lymphatic system cancer	3.98e-05	0.000501	CcSEcCtD
Epirubicin—Hypertension—Mitoxantrone—lymphatic system cancer	3.98e-05	0.0005	CcSEcCtD
Epirubicin—Pain—Bleomycin—lymphatic system cancer	3.96e-05	0.000499	CcSEcCtD
Epirubicin—Thrombocytopenia—Carmustine—lymphatic system cancer	3.96e-05	0.000498	CcSEcCtD
Epirubicin—Headache—Fludarabine—lymphatic system cancer	3.96e-05	0.000498	CcSEcCtD
Epirubicin—Tachycardia—Carmustine—lymphatic system cancer	3.95e-05	0.000497	CcSEcCtD
Epirubicin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	3.94e-05	0.000495	CcSEcCtD
Epirubicin—Chest pain—Mitoxantrone—lymphatic system cancer	3.92e-05	0.000494	CcSEcCtD
Epirubicin—Myalgia—Mitoxantrone—lymphatic system cancer	3.92e-05	0.000494	CcSEcCtD
Epirubicin—Arthralgia—Mitoxantrone—lymphatic system cancer	3.92e-05	0.000494	CcSEcCtD
Epirubicin—Anxiety—Mitoxantrone—lymphatic system cancer	3.91e-05	0.000492	CcSEcCtD
Epirubicin—Lethargy—Methotrexate—lymphatic system cancer	3.89e-05	0.000489	CcSEcCtD
Epirubicin—Cerebrovascular accident—Methotrexate—lymphatic system cancer	3.89e-05	0.000489	CcSEcCtD
Epirubicin—Discomfort—Mitoxantrone—lymphatic system cancer	3.88e-05	0.000488	CcSEcCtD
Epirubicin—Oedema—Vincristine—lymphatic system cancer	3.86e-05	0.000486	CcSEcCtD
Epirubicin—Anaphylactic shock—Vincristine—lymphatic system cancer	3.86e-05	0.000486	CcSEcCtD
Epirubicin—Anorexia—Carmustine—lymphatic system cancer	3.86e-05	0.000485	CcSEcCtD
Epirubicin—Infection—Vincristine—lymphatic system cancer	3.84e-05	0.000483	CcSEcCtD
Epirubicin—Feeling abnormal—Bleomycin—lymphatic system cancer	3.82e-05	0.00048	CcSEcCtD
Epirubicin—Osteoarthritis—Methotrexate—lymphatic system cancer	3.81e-05	0.00048	CcSEcCtD
Epirubicin—Confusional state—Mitoxantrone—lymphatic system cancer	3.79e-05	0.000477	CcSEcCtD
Epirubicin—Nervous system disorder—Vincristine—lymphatic system cancer	3.79e-05	0.000476	CcSEcCtD
Epirubicin—Thrombocytopenia—Vincristine—lymphatic system cancer	3.78e-05	0.000476	CcSEcCtD
Epirubicin—Hypotension—Carmustine—lymphatic system cancer	3.78e-05	0.000476	CcSEcCtD
Epirubicin—Oedema—Mitoxantrone—lymphatic system cancer	3.76e-05	0.000473	CcSEcCtD
Epirubicin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	3.76e-05	0.000473	CcSEcCtD
Epirubicin—Nausea—Fludarabine—lymphatic system cancer	3.75e-05	0.000472	CcSEcCtD
Epirubicin—Infection—Mitoxantrone—lymphatic system cancer	3.74e-05	0.00047	CcSEcCtD
Epirubicin—Hyperhidrosis—Vincristine—lymphatic system cancer	3.73e-05	0.00047	CcSEcCtD
Epirubicin—Shock—Mitoxantrone—lymphatic system cancer	3.7e-05	0.000465	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.69e-05	0.000464	CcSEcCtD
Epirubicin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.68e-05	0.000463	CcSEcCtD
Epirubicin—Urticaria—Bleomycin—lymphatic system cancer	3.68e-05	0.000463	CcSEcCtD
Epirubicin—Anorexia—Vincristine—lymphatic system cancer	3.68e-05	0.000463	CcSEcCtD
Epirubicin—Tachycardia—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000462	CcSEcCtD
Epirubicin—Body temperature increased—Bleomycin—lymphatic system cancer	3.66e-05	0.000461	CcSEcCtD
Epirubicin—Insomnia—Carmustine—lymphatic system cancer	3.66e-05	0.00046	CcSEcCtD
Epirubicin—Skin disorder—Mitoxantrone—lymphatic system cancer	3.65e-05	0.00046	CcSEcCtD
Epirubicin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	3.64e-05	0.000457	CcSEcCtD
Epirubicin—Paraesthesia—Carmustine—lymphatic system cancer	3.63e-05	0.000457	CcSEcCtD
Epirubicin—Mood swings—Methotrexate—lymphatic system cancer	3.61e-05	0.000454	CcSEcCtD
Epirubicin—Hypotension—Vincristine—lymphatic system cancer	3.61e-05	0.000454	CcSEcCtD
Epirubicin—Dyspnoea—Carmustine—lymphatic system cancer	3.61e-05	0.000454	CcSEcCtD
Epirubicin—Somnolence—Carmustine—lymphatic system cancer	3.6e-05	0.000452	CcSEcCtD
Epirubicin—Anorexia—Mitoxantrone—lymphatic system cancer	3.58e-05	0.000451	CcSEcCtD
Epirubicin—Ataxia—Methotrexate—lymphatic system cancer	3.58e-05	0.000451	CcSEcCtD
Epirubicin—Liver function test abnormal—Methotrexate—lymphatic system cancer	3.52e-05	0.000443	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.52e-05	0.000443	CcSEcCtD
Epirubicin—Decreased appetite—Carmustine—lymphatic system cancer	3.52e-05	0.000442	CcSEcCtD
Epirubicin—Hypotension—Mitoxantrone—lymphatic system cancer	3.51e-05	0.000442	CcSEcCtD
Epirubicin—Insomnia—Vincristine—lymphatic system cancer	3.49e-05	0.000439	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.49e-05	0.000439	CcSEcCtD
Epirubicin—Paraesthesia—Vincristine—lymphatic system cancer	3.47e-05	0.000436	CcSEcCtD
Epirubicin—Pain—Carmustine—lymphatic system cancer	3.46e-05	0.000435	CcSEcCtD
Epirubicin—Constipation—Carmustine—lymphatic system cancer	3.46e-05	0.000435	CcSEcCtD
Epirubicin—Breast disorder—Methotrexate—lymphatic system cancer	3.45e-05	0.000433	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	3.43e-05	0.000432	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.43e-05	0.000431	CcSEcCtD
Epirubicin—Hypersensitivity—Bleomycin—lymphatic system cancer	3.41e-05	0.00043	CcSEcCtD
Epirubicin—Paraesthesia—Mitoxantrone—lymphatic system cancer	3.38e-05	0.000425	CcSEcCtD
Epirubicin—Decreased appetite—Vincristine—lymphatic system cancer	3.36e-05	0.000422	CcSEcCtD
Epirubicin—Dyspnoea—Mitoxantrone—lymphatic system cancer	3.35e-05	0.000422	CcSEcCtD
Epirubicin—Somnolence—Mitoxantrone—lymphatic system cancer	3.34e-05	0.000421	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	3.33e-05	0.000419	CcSEcCtD
Epirubicin—Feeling abnormal—Carmustine—lymphatic system cancer	3.33e-05	0.000419	CcSEcCtD
Epirubicin—Fatigue—Vincristine—lymphatic system cancer	3.33e-05	0.000419	CcSEcCtD
Epirubicin—Asthenia—Bleomycin—lymphatic system cancer	3.33e-05	0.000418	CcSEcCtD
Epirubicin—Dyspepsia—Mitoxantrone—lymphatic system cancer	3.31e-05	0.000416	CcSEcCtD
Epirubicin—Gastrointestinal pain—Carmustine—lymphatic system cancer	3.31e-05	0.000416	CcSEcCtD
Epirubicin—Pain—Vincristine—lymphatic system cancer	3.3e-05	0.000415	CcSEcCtD
Epirubicin—Constipation—Vincristine—lymphatic system cancer	3.3e-05	0.000415	CcSEcCtD
Epirubicin—Asthma—Methotrexate—lymphatic system cancer	3.29e-05	0.000414	CcSEcCtD
Epirubicin—Pruritus—Bleomycin—lymphatic system cancer	3.28e-05	0.000412	CcSEcCtD
Epirubicin—Decreased appetite—Mitoxantrone—lymphatic system cancer	3.27e-05	0.000411	CcSEcCtD
Epirubicin—Eosinophilia—Methotrexate—lymphatic system cancer	3.26e-05	0.00041	CcSEcCtD
Epirubicin—Fatigue—Mitoxantrone—lymphatic system cancer	3.24e-05	0.000408	CcSEcCtD
Epirubicin—Pancreatitis—Methotrexate—lymphatic system cancer	3.23e-05	0.000406	CcSEcCtD
Epirubicin—Constipation—Mitoxantrone—lymphatic system cancer	3.22e-05	0.000405	CcSEcCtD
Epirubicin—Pain—Mitoxantrone—lymphatic system cancer	3.22e-05	0.000405	CcSEcCtD
Epirubicin—Body temperature increased—Carmustine—lymphatic system cancer	3.2e-05	0.000402	CcSEcCtD
Epirubicin—Abdominal pain—Carmustine—lymphatic system cancer	3.2e-05	0.000402	CcSEcCtD
Epirubicin—Gastrointestinal pain—Vincristine—lymphatic system cancer	3.16e-05	0.000397	CcSEcCtD
Epirubicin—Pancytopenia—Methotrexate—lymphatic system cancer	3.13e-05	0.000394	CcSEcCtD
Epirubicin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	3.1e-05	0.00039	CcSEcCtD
Epirubicin—Neutropenia—Methotrexate—lymphatic system cancer	3.08e-05	0.000388	CcSEcCtD
Epirubicin—Dysuria—Methotrexate—lymphatic system cancer	3.08e-05	0.000388	CcSEcCtD
Epirubicin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	3.08e-05	0.000387	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	3.06e-05	0.000385	CcSEcCtD
Epirubicin—Abdominal pain—Vincristine—lymphatic system cancer	3.05e-05	0.000384	CcSEcCtD
Epirubicin—Body temperature increased—Vincristine—lymphatic system cancer	3.05e-05	0.000384	CcSEcCtD
Epirubicin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	3.01e-05	0.000378	CcSEcCtD
Epirubicin—Urticaria—Mitoxantrone—lymphatic system cancer	2.99e-05	0.000376	CcSEcCtD
Epirubicin—Hypersensitivity—Carmustine—lymphatic system cancer	2.98e-05	0.000375	CcSEcCtD
Epirubicin—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.97e-05	0.000374	CcSEcCtD
Epirubicin—Abdominal pain—Mitoxantrone—lymphatic system cancer	2.97e-05	0.000374	CcSEcCtD
Epirubicin—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	2.97e-05	0.0145	CbGdCrCtD
Epirubicin—Pneumonia—Methotrexate—lymphatic system cancer	2.95e-05	0.000372	CcSEcCtD
Epirubicin—Vomiting—Bleomycin—lymphatic system cancer	2.95e-05	0.000371	CcSEcCtD
Epirubicin—Drowsiness—Methotrexate—lymphatic system cancer	2.94e-05	0.00037	CcSEcCtD
Epirubicin—Infestation NOS—Methotrexate—lymphatic system cancer	2.94e-05	0.00037	CcSEcCtD
Epirubicin—Infestation—Methotrexate—lymphatic system cancer	2.94e-05	0.00037	CcSEcCtD
Epirubicin—Rash—Bleomycin—lymphatic system cancer	2.92e-05	0.000368	CcSEcCtD
Epirubicin—Dermatitis—Bleomycin—lymphatic system cancer	2.92e-05	0.000367	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	2.91e-05	0.000366	CcSEcCtD
Epirubicin—Asthenia—Carmustine—lymphatic system cancer	2.9e-05	0.000365	CcSEcCtD
Epirubicin—Renal failure—Methotrexate—lymphatic system cancer	2.89e-05	0.000363	CcSEcCtD
Epirubicin—Stomatitis—Methotrexate—lymphatic system cancer	2.86e-05	0.00036	CcSEcCtD
Epirubicin—Conjunctivitis—Methotrexate—lymphatic system cancer	2.86e-05	0.000359	CcSEcCtD
Epirubicin—Hypersensitivity—Vincristine—lymphatic system cancer	2.85e-05	0.000358	CcSEcCtD
Epirubicin—Sweating—Methotrexate—lymphatic system cancer	2.82e-05	0.000354	CcSEcCtD
Epirubicin—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	2.8e-05	0.0137	CbGdCrCtD
Epirubicin—Haematuria—Methotrexate—lymphatic system cancer	2.8e-05	0.000352	CcSEcCtD
Epirubicin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.78e-05	0.00035	CcSEcCtD
Epirubicin—Epistaxis—Methotrexate—lymphatic system cancer	2.77e-05	0.000349	CcSEcCtD
Epirubicin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.77e-05	0.000349	CcSEcCtD
Epirubicin—Asthenia—Vincristine—lymphatic system cancer	2.77e-05	0.000349	CcSEcCtD
Epirubicin—Diarrhoea—Carmustine—lymphatic system cancer	2.77e-05	0.000348	CcSEcCtD
Epirubicin—Nausea—Bleomycin—lymphatic system cancer	2.75e-05	0.000346	CcSEcCtD
Epirubicin—Agranulocytosis—Methotrexate—lymphatic system cancer	2.74e-05	0.000345	CcSEcCtD
Epirubicin—Asthenia—Mitoxantrone—lymphatic system cancer	2.7e-05	0.000339	CcSEcCtD
Epirubicin—Dizziness—Carmustine—lymphatic system cancer	2.68e-05	0.000337	CcSEcCtD
Epirubicin—Haemoglobin—Methotrexate—lymphatic system cancer	2.65e-05	0.000333	CcSEcCtD
Epirubicin—Diarrhoea—Vincristine—lymphatic system cancer	2.64e-05	0.000332	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—lymphatic system cancer	2.64e-05	0.000332	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—lymphatic system cancer	2.64e-05	0.000332	CcSEcCtD
Epirubicin—Pharyngitis—Methotrexate—lymphatic system cancer	2.62e-05	0.000329	CcSEcCtD
Epirubicin—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.6e-05	0.000328	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—lymphatic system cancer	2.59e-05	0.000325	CcSEcCtD
Epirubicin—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.57e-05	0.000324	CcSEcCtD
Epirubicin—Vomiting—Carmustine—lymphatic system cancer	2.57e-05	0.000324	CcSEcCtD
Epirubicin—Dizziness—Vincristine—lymphatic system cancer	2.55e-05	0.000321	CcSEcCtD
Epirubicin—Rash—Carmustine—lymphatic system cancer	2.55e-05	0.000321	CcSEcCtD
Epirubicin—Dermatitis—Carmustine—lymphatic system cancer	2.55e-05	0.000321	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—lymphatic system cancer	2.54e-05	0.00032	CcSEcCtD
Epirubicin—Headache—Carmustine—lymphatic system cancer	2.53e-05	0.000319	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—lymphatic system cancer	2.49e-05	0.000314	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—lymphatic system cancer	2.46e-05	0.00031	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—lymphatic system cancer	2.46e-05	0.000309	CcSEcCtD
Epirubicin—Vomiting—Vincristine—lymphatic system cancer	2.46e-05	0.000309	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—lymphatic system cancer	2.45e-05	0.000308	CcSEcCtD
Epirubicin—Rash—Vincristine—lymphatic system cancer	2.43e-05	0.000306	CcSEcCtD
Epirubicin—Dermatitis—Vincristine—lymphatic system cancer	2.43e-05	0.000306	CcSEcCtD
Epirubicin—Headache—Vincristine—lymphatic system cancer	2.42e-05	0.000304	CcSEcCtD
Epirubicin—Nausea—Carmustine—lymphatic system cancer	2.4e-05	0.000302	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—lymphatic system cancer	2.39e-05	0.000301	CcSEcCtD
Epirubicin—Vomiting—Mitoxantrone—lymphatic system cancer	2.39e-05	0.000301	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—lymphatic system cancer	2.38e-05	0.0003	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.38e-05	0.000299	CcSEcCtD
Epirubicin—Rash—Mitoxantrone—lymphatic system cancer	2.37e-05	0.000298	CcSEcCtD
Epirubicin—Dermatitis—Mitoxantrone—lymphatic system cancer	2.37e-05	0.000298	CcSEcCtD
Epirubicin—Chills—Methotrexate—lymphatic system cancer	2.37e-05	0.000298	CcSEcCtD
Epirubicin—Headache—Mitoxantrone—lymphatic system cancer	2.36e-05	0.000296	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—lymphatic system cancer	2.33e-05	0.000293	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—lymphatic system cancer	2.31e-05	0.000291	CcSEcCtD
Epirubicin—Erythema—Methotrexate—lymphatic system cancer	2.3e-05	0.000289	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—lymphatic system cancer	2.3e-05	0.000289	CcSEcCtD
Epirubicin—Nausea—Vincristine—lymphatic system cancer	2.29e-05	0.000289	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—lymphatic system cancer	2.25e-05	0.000283	CcSEcCtD
Epirubicin—Nausea—Mitoxantrone—lymphatic system cancer	2.23e-05	0.000281	CcSEcCtD
Epirubicin—Back pain—Methotrexate—lymphatic system cancer	2.22e-05	0.000279	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—lymphatic system cancer	2.16e-05	0.000272	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—lymphatic system cancer	2.13e-05	0.000268	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—lymphatic system cancer	2.12e-05	0.000267	CcSEcCtD
Epirubicin—Malaise—Methotrexate—lymphatic system cancer	2.07e-05	0.00026	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—lymphatic system cancer	2.06e-05	0.000259	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—lymphatic system cancer	2.06e-05	0.000259	CcSEcCtD
Epirubicin—Cough—Methotrexate—lymphatic system cancer	2e-05	0.000252	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—lymphatic system cancer	1.99e-05	0.00025	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—lymphatic system cancer	1.95e-05	0.000246	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—lymphatic system cancer	1.95e-05	0.000246	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—lymphatic system cancer	1.95e-05	0.000246	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	1.94e-05	0.000244	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—lymphatic system cancer	1.93e-05	0.000243	CcSEcCtD
Epirubicin—Confusional state—Methotrexate—lymphatic system cancer	1.89e-05	0.000238	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.87e-05	0.000236	CcSEcCtD
Epirubicin—Infection—Methotrexate—lymphatic system cancer	1.86e-05	0.000234	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—lymphatic system cancer	1.84e-05	0.000231	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.83e-05	0.000231	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—lymphatic system cancer	1.82e-05	0.000229	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—lymphatic system cancer	1.81e-05	0.000228	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—lymphatic system cancer	1.79e-05	0.000225	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—lymphatic system cancer	1.75e-05	0.00022	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.71e-05	0.000215	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—lymphatic system cancer	1.69e-05	0.000213	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—lymphatic system cancer	1.68e-05	0.000212	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—lymphatic system cancer	1.67e-05	0.00021	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—lymphatic system cancer	1.67e-05	0.00021	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—lymphatic system cancer	1.65e-05	0.000207	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—lymphatic system cancer	1.63e-05	0.000205	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.62e-05	0.000203	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—lymphatic system cancer	1.62e-05	0.000203	CcSEcCtD
Epirubicin—Pain—Methotrexate—lymphatic system cancer	1.6e-05	0.000202	CcSEcCtD
Epirubicin—Feeling abnormal—Methotrexate—lymphatic system cancer	1.54e-05	0.000194	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.53e-05	0.000193	CcSEcCtD
Epirubicin—Urticaria—Methotrexate—lymphatic system cancer	1.49e-05	0.000187	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—lymphatic system cancer	1.48e-05	0.000186	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—lymphatic system cancer	1.48e-05	0.000186	CcSEcCtD
Epirubicin—Hypersensitivity—Methotrexate—lymphatic system cancer	1.38e-05	0.000174	CcSEcCtD
Epirubicin—Asthenia—Methotrexate—lymphatic system cancer	1.34e-05	0.000169	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—lymphatic system cancer	1.33e-05	0.000167	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—lymphatic system cancer	1.28e-05	0.000161	CcSEcCtD
Epirubicin—Dizziness—Methotrexate—lymphatic system cancer	1.24e-05	0.000156	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—lymphatic system cancer	1.19e-05	0.00015	CcSEcCtD
Epirubicin—Rash—Methotrexate—lymphatic system cancer	1.18e-05	0.000149	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—lymphatic system cancer	1.18e-05	0.000148	CcSEcCtD
Epirubicin—Headache—Methotrexate—lymphatic system cancer	1.17e-05	0.000148	CcSEcCtD
Epirubicin—Nausea—Methotrexate—lymphatic system cancer	1.11e-05	0.00014	CcSEcCtD
